Nitric oxide attenuates interleukin 2-induced lung injury

British Journal of Surgery

Volumn 84, Issue 4, 1997, Pages 540-542

  Bouchier Hayes, D ^b   Abdih, H ^a   Kelly, C J ^a   Barry, M ^a   Redmond, H P ^a   Burke, P ^a   Tanner, A ^b   Bouchier Hayes, D J ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MYELOPEROXIDASE; NITRIC OXIDE; NITROPRUSSIDE SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; LUNG INJURY; LUNG LAVAGE; MALE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; VASCULAR DISEASE;

EID: 0030949822     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800840430     Document Type: Article

References (24)

1. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889-97.
2. West WH, Tauer KW, Yannelli JR et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898-905.
3. Parkinson DR. Interleukin-2 in cancer therapy. Semin Oncol 1988; 15(Suppl. 6): 10-26.
4. Lotze MT, Matory YL, Rayner AA et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58: 2764-72.
5. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 9: 964-704.
6. Klausner JM, Paterson IS, Morel NML et al. Role of thromboxane in interleukin 2-induced lung injury in sheep. Cancer Res 1989; 49: 3542-9.
7. Welbourn R, Goldman G, Kobzik L, Valeri CR, Shepro D, Hechtman HB. Involvement of thromboxane and neutrophils in multiple-system organ edema with interleukin-2. Ann Surg 1990; 212: 728-33.
8. Ohkubo C, Bigos D, Jian RK. Interleukin 2 induced leukocyte adhesion to the normal and tumor microvascular endothelium in vitro and its inhibition by dextran sulfate: implications for vascular leak syndrome. Cancer Res 1991; 51: 1561-3.
9. Welbourn R, Goldman G, Kobzik L, Paterson I, Shepro D, Hechtman HB. Interleukin-2 induces early multisystem organ edema mediated by neutrophils. Ann Surg 1991; 214: 181-6.
10. Edwards MJ, Miller FN, Sims DE, Abney DL, Schuschke DA, Corey TS. Interleukin 2 acutely induces platelet and neutrophil-endothelial adherence and macromolecular leakage. Cancer Res 1992; 52: 3425-31.
11. Baars JW, Hack CE, Wagstaff J et al. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. Br J Cancer 1992; 65: 96-101.
12. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-42.
13. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454-6.
14. McCall TB, Boughton-Smith NK, Palmer RMJ, Whittle BJR, Moncada S. Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J 1989; 261: 293-6.
15. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991; 88: 4651-5.
16. Abdih H, Kelly CJ, Bouchier-Hayes D et al. Nitric oxide (endothelium-derived relaxing factor) attenuates revascularization-induced lung injury. J Surg Res 1994; 57: 39-43.
17. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78: 206-9.
18. Williams RN, Paterson CA, Eakins KE, Bhattacherjee P. Quantification of ocular inflammation: evaluation of polymorphonuclear leucocyte infiltration by measuring myeloperoxidase activity. Curr Eye Res 1983; 2: 465-70.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
20. Clancy RM, Leszcynska-Piziak J, Abramson SB. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest 1992; 90: 1116-21.
21. Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am J Physiol 1992; 262: H611-15.
22. G-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit Care Med 1995; 23: 1018-24.
23. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328: 399-405.
24. Efron DT, Kirk ST, Regan MC, Wasserkrug HL, Barbul A. Nitric oxide generation from L-arginine is required for optimal human peripheral blood lymphocyte DNA synthesis. Surgery 1991; 110: 327-34.